دورية أكاديمية
أعرض في EDS

A Randomized Clinical Trial of Intratracheal Administration of Surfactant and Budesonide Combination in Comparison to Surfactant for Prevention of Bronchopulmonary Dysplasia.

التفاصيل البيبلوغرافية
العنوان: A Randomized Clinical Trial of Intratracheal Administration of Surfactant and Budesonide Combination in Comparison to Surfactant for Prevention of Bronchopulmonary Dysplasia.
المؤلفون: Gharehbaghi MM; Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Ganji S; Pediatrics and Neonatology Department, Tabriz University of Medical Sciences, Tabriz, Iran., Mahallei M; Pediatrics and Neonatology Department, Tabriz University of Medical Sciences, Tabriz, Iran.
المصدر: Oman medical journal [Oman Med J] 2021 Jul 31; Vol. 36 (4), pp. e289. Date of Electronic Publication: 2021 Jul 31 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Oman Medical Specialty Board Country of Publication: Oman NLM ID: 101526350 Publication Model: eCollection Cited Medium: Print ISSN: 1999-768X (Print) Linking ISSN: 1999768X NLM ISO Abbreviation: Oman Med J Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Muscat : Oman Medical Specialty Board
مستخلص: Objectives: Bronchopulmonary dysplasia (BPD) remains a major problem in preterm infants occurring in up to 50% of infants born at < 28 weeks gestational age. Inflammation plays an important role in the pathogenesis of BPD. This study was conducted to evaluate the efficacy of intratracheal budesonide administration in combination with a surfactant in preventing BPD in preterm infants.
Methods: In a randomized clinical trial, 128 preterm infants at < 30 weeks gestational age and weighing < 1500 g at birth were studied. All had respiratory distress syndrome (RDS) and needed surfactant replacement therapy. They were randomly allocated into two groups; surfactant group (n = 64) and surfactant + budesonide group 
(n = 64). Neonates in the surfactant group received intratracheal Curosurf 200 mg/kg/dose. Patients in the surfactant + budesonide group were treated with intratracheal instillation of a mixed suspension of budesonide 0.25 mg/kg and Curosurf 200 mg/kg/dose. Neonates were followed untill discharge for the primary outcome which was BPD and secondary outcomes including sepsis, patent ductus arteriosus (PDA), retinopathy of prematurity (ROP), and necrotizing enterocolitis (NEC).
Results: The mean gestational age and birth weight of the studied neonates were 28.3±1.6 weeks and 1072.0±180.0 g, respectively. The demographic characteristics and RDS score were similar in the two groups. BPD occurred in 24 (37.5%) neonates in the surfactant + budesonide group and 38 (59.4%) neonates in surfactant group, p = 0.040. Hospital stay was 29.7±19.2 days (median = 30 days) in the surfactant group and 23.3±18.1 days (median = 20 days) in the surfactant + budesonide group, p = 0.050. The rates of sepsis, PDA, ROP, and NEC were not significantly different in the two groups.
Conclusions: The use of budesonide in addition to surfactant for rescue therapy of RDS in preterm infants decreases the incidence of BPD and duration of respiratory support significantly. Large adequately powered clinical trials with long-term safety assessments are needed to confirm our findings before its routine use can be recommended.
(The OMJ is Published Bimonthly and Copyrighted 2021 by the OMSB.)
References: J Pediatr. 1991 Sep;119(3):417-23. (PMID: 1880657)
Pediatr Pulmonol. 1997 Nov;24(5):331-6. (PMID: 9407566)
Neonatology. 2015;107(4):358-9. (PMID: 26044104)
Pediatrics. 2009 Sep;124(3):e450-8. (PMID: 19706590)
Eur J Pediatr. 2011 Dec;170(12):1495-505. (PMID: 21465122)
Neonatology. 2008;94(3):164-9. (PMID: 18612213)
Cochrane Database Syst Rev. 2000;(2):CD000511. (PMID: 10796380)
J Pediatr. 1992 Jun;120(6):938-46. (PMID: 1593356)
Pediatr Res. 2002 Dec;52(6):973-8. (PMID: 12438678)
Pediatr Pulmonol. 2013 Feb;48(2):151-9. (PMID: 22489085)
J Pharm Sci. 2002 Jun;91(6):1561-7. (PMID: 12115854)
JAMA. 2015 Sep 8;314(10):1039-51. (PMID: 26348753)
Pediatr Pulmonol. 2018 Jan;53(1):28-35. (PMID: 29028158)
Pediatrics. 1987 Jan;79(1):26-30. (PMID: 3797169)
Pediatr Pulmonol. 1995 Jun;19(6):371-8. (PMID: 7567218)
BMC Pulm Med. 2017 Dec 15;17(1):207. (PMID: 29246209)
Pediatr Pulmonol. 2004 Feb;37(2):137-48. (PMID: 14730659)
Arch Dis Child Fetal Neonatal Ed. 1995 Jul;73(1):F1-3. (PMID: 7552588)
J Perinat Med. 2004;32(3):272-7. (PMID: 15188804)
Lancet. 2017 Apr 22;389(10079):1649-1659. (PMID: 28443559)
Pediatrics. 2008 Sep;122(3):479-85. (PMID: 18762515)
Am J Respir Crit Care Med. 2001 Jun;163(7):1723-9. (PMID: 11401896)
Am J Respir Crit Care Med. 2016 Jan 1;193(1):86-95. (PMID: 26351971)
J Perinatol. 2008 Jun;28(6):420-6. (PMID: 18337740)
Pediatrics. 2008 May;121(5):e1310-8. (PMID: 18426851)
Clin Perinatol. 1987 Sep;14(3):621-33. (PMID: 3311542)
Pediatrics. 2000 Jun;105(6):1194-201. (PMID: 10835057)
Am J Obstet Gynecol. 2007 Feb;196(2):147.e1-8. (PMID: 17306659)
J Pediatr. 1991 Aug;119(2):285-92. (PMID: 1861218)
J Paediatr Child Health. 1992 Aug;28(4):301-5. (PMID: 1497957)
Pediatrics. 2008 Feb;121(2):419-32. (PMID: 18245434)
Arch Dis Child Fetal Neonatal Ed. 2008 Jan;93(1):F58-63. (PMID: 17848504)
J Pediatr. 1989 Jul;115(1):115-20. (PMID: 2500509)
فهرسة مساهمة: Keywords: Bronchopulmonary Dysplasia; Budesonide; Infant; Infant, Premature; Respiratory Distress Syndrome
تواريخ الأحداث: Date Created: 20210827 Latest Revision: 20220426
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8376750
DOI: 10.5001/omj.2021.84
PMID: 34447583
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-768X
DOI:10.5001/omj.2021.84